CLINICAL_TRIALS
trial_result
· 2013-01-30
Clinical Trial Update: Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks [Phase 2]
Summary
Phase 2 trial results for CP-690,550 (tofacitinib) as monotherapy at three dose levels versus placebo in rheumatoid arthritis; results were posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2013-01-30